Towa Pharmaceutical Co Ltd (JP:4553)
:4553
Want to see JP:4553 full AI Analyst Report?
4553 Stock Chart & Stats
¥3620.00
-¥90.00(-2.71%)
At close: 4:00 PM EST
¥3620.00
-¥90.00(-2.71%)
Day’s Range― - ―
52-Week Range¥2,764.00 - ¥4,490.00
Previous CloseN/A
Volume116.60K
Average Volume (3M)112.31K
Market Cap
¥181.60B
Enterprise Value¥367.02B
Total Cash (Recent Filing)¥45.31B
Total Debt (Recent Filing)¥226.74B
Price to Earnings (P/E)34.7
Beta0.65
Next Earnings
Aug 06, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield2.14%
Share Statistics
EPS (TTM)106.65
Shares Outstanding51,516,000
10 Day Avg. Volume138,760
30 Day Avg. Volume112,306
Financial Highlights & Ratios
PEG Ratio-0.52
Price to Book (P/B)1.11
Price to Sales (P/S)0.72
P/FCF Ratio24.19
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
¥5,600.00Price Target Upside54.70% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)438.61
Revenue Forecast (FY)¥302.60B
Bulls Say, Bears Say
Bulls Say
Durable Generics Business ModelTowa’s core model—manufacture and sale of post-patent generic medicines into Japan’s national health system—creates recurring, predictable demand. A broad portfolio and institutional distribution reduce single-product risk and support stable revenue and capacity utilization over multiple years.
Sustained Revenue GrowthConsistent top-line expansion over several years suggests successful launches and portfolio replenishment as patents expire. Persistent revenue growth supports economies of scale in manufacturing, improves bargaining leverage with distributors, and underpins longer-term margin recovery when cost control is maintained.
Improving Cash Generation TrajectoryThe shift to positive free cash flow and stronger operating cash flow in 2025–2026 is a structural inflection that enhances financial flexibility. Sustained cash generation enables capex for capacity, working-capital resilience, and options to reduce leverage or fund strategic partnerships without dilutive financing.
Bears Say
Elevated LeverageA debt-heavy capital structure reduces resilience to profit shocks and raises interest obligations. With leverage elevated across multiple years, the company faces less financial flexibility for investment or M&A and greater refinancing risk if earnings or cash flows weaken again.
Volatile Profitability And Earnings QualityEarnings swings—especially when operating profit is stable but net income falls—point to non-operating costs, tax or one-off items that impair predictable returns. Persistent volatility complicates planning, dividend policy, and credit metrics, increasing long-term investor and creditor uncertainty.
Inconsistent Free Cash Flow ProfileMulti-year negative free cash flow before a 2026 recovery indicates periods where capital spending or working capital outlays outpaced internal generation. Recurring cash deficits heighten reliance on external financing and constrain sustained investment in capacity or quality initiatives critical in pharmaceuticals.
Towa Pharmaceutical Co News
4553 FAQ
What was Towa Pharmaceutical Co Ltd’s price range in the past 12 months?
Towa Pharmaceutical Co Ltd lowest stock price was ¥2764.00 and its highest was ¥4490.00 in the past 12 months.
What is Towa Pharmaceutical Co Ltd’s market cap?
Towa Pharmaceutical Co Ltd’s market cap is ¥181.60B.
When is Towa Pharmaceutical Co Ltd’s upcoming earnings report date?
Towa Pharmaceutical Co Ltd’s upcoming earnings report date is Aug 06, 2026 which is in 46 days.
How were Towa Pharmaceutical Co Ltd’s earnings last quarter?
Towa Pharmaceutical Co Ltd released its earnings results on May 14, 2026. The company reported -¥240.35 earnings per share for the quarter, missing the consensus estimate of ¥107.89 by -¥348.24.
Is Towa Pharmaceutical Co Ltd overvalued?
According to Wall Street analysts Towa Pharmaceutical Co Ltd’s price is currently Undervalued.
Does Towa Pharmaceutical Co Ltd pay dividends?
Towa Pharmaceutical Co Ltd pays a Semiannually dividend of ¥40 which represents an annual dividend yield of 2.14%. See more information on Towa Pharmaceutical Co Ltd dividends here
What is Towa Pharmaceutical Co Ltd’s EPS estimate?
Towa Pharmaceutical Co Ltd’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Towa Pharmaceutical Co Ltd have?
Towa Pharmaceutical Co Ltd has 51,516,000 shares outstanding.
What happened to Towa Pharmaceutical Co Ltd’s price movement after its last earnings report?
Towa Pharmaceutical Co Ltd reported an EPS of -¥240.35 in its last earnings report, missing expectations of ¥107.89. Following the earnings report the stock price went up 0.881%.
Which hedge fund is a major shareholder of Towa Pharmaceutical Co Ltd?
Currently, no hedge funds are holding shares in JP:4553
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Towa Pharmaceutical Co Ltd
Towa Pharmaceutical Co., Ltd., along with its subsidiaries, is actively engaged in the entire pharmaceutical lifecycle within Japan, from researching and developing to manufacturing and marketing prescription medications, active pharmaceutical ingredients, and intermediate compounds. The company's extensive product offerings target critical therapeutic areas, including diabetes, digestive and nervous system disorders, and allergic conditions. Furthermore, their portfolio encompasses vitamins, antibiotics, and oncology treatments. With a comprehensive collection of approximately 700 distinct drug products, Towa Pharmaceutical Co., Ltd. was founded in 1951 and is headquartered in Osaka, Japan.
4553 Stock 12 Month Forecast
Average Price Target
¥5,600.00
▲(54.70% Upside)
Technical Analysis
Kaken Pharmaceutical Co
―
Kissei Pharmaceutical Co
―
Mochida Pharmaceutical Co., Ltd.
―
KYORIN Pharmaceutical Co.,Ltd.
―
SAWAI GROUP HOLDINGS Co., Ltd.
―
Options Prices
Currently, No data available
---